Phibro Animal Health (NASDAQ:PAHC – Free Report) had its price target lifted by Bank of America from $13.00 to $15.00 in a research report report published on Friday, Benzinga reports. The firm currently has an underperform rating on the stock.
Separately, Barclays raised their price objective on Phibro Animal Health from $10.00 to $13.00 and gave the company an underweight rating in a research note on Friday, May 10th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Phibro Animal Health has a consensus rating of Hold and an average price target of $13.25.
Get Our Latest Stock Analysis on PAHC
Phibro Animal Health Trading Down 2.2 %
Phibro Animal Health Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 25th. Investors of record on Wednesday, September 4th will be given a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, September 4th. This represents a $0.48 annualized dividend and a dividend yield of 2.29%. Phibro Animal Health’s payout ratio is 150.00%.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the stock. Dana Investment Advisors Inc. boosted its position in shares of Phibro Animal Health by 17.2% during the second quarter. Dana Investment Advisors Inc. now owns 513,926 shares of the company’s stock valued at $8,619,000 after buying an additional 75,546 shares during the last quarter. Truist Financial Corp purchased a new position in shares of Phibro Animal Health during the second quarter valued at approximately $308,000. Brandes Investment Partners LP boosted its position in shares of Phibro Animal Health by 1.2% during the second quarter. Brandes Investment Partners LP now owns 2,405,629 shares of the company’s stock valued at $40,521,000 after buying an additional 29,071 shares during the last quarter. Algert Global LLC purchased a new position in shares of Phibro Animal Health during the second quarter valued at approximately $193,000. Finally, Deerfield Management Company L.P. Series C boosted its position in shares of Phibro Animal Health by 102.4% during the second quarter. Deerfield Management Company L.P. Series C now owns 25,164 shares of the company’s stock valued at $422,000 after buying an additional 12,731 shares during the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
Further Reading
- Five stocks we like better than Phibro Animal Health
- What is a Death Cross in Stocks?
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- How to Invest in the Best Canadian Stocks
- Why Dell Can Continue Winning in AI and Beyond
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.